Contact this trialFirst, we need to learn more about you.
Cancer Vaccine
VGX-3100 + Electroporation for High-Grade Anal Lesions in HIV
Recruiting1 awardPhase 2
Los Angeles, California
This trial is studying the use of a human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine (VGX-3100) and electroporation to treat patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.